| Breast Cancer |
1 |
0.71 |
| Carbon Dioxide Laser |
0 |
0.63 |
| Vagina |
0 |
0.28 |
| Menopause |
0 |
0.26 |
| Sexual Dysfunction in Female |
0 |
0.26 |
| Lichen Sclerosus et Atrophicus |
0 |
0.25 |
| Aesthetic Medicine |
0 |
0.24 |
| Atrophic Vaginitis |
0 |
0.23 |
| Estrogen |
0 |
0.21 |
| Physical Medicine and Rehabilitation (PMR) |
0 |
0.21 |
| Cosmetic Dermatology |
0 |
0.19 |
| Dermatologic Surgery |
0 |
0.19 |
| Sexual Dysfunction |
0 |
0.18 |
| Pain Management |
0 |
0.15 |
| Urinary Incontinence |
0 |
0.14 |
| Selective Estrogen Receptor Modulators |
0 |
0.13 |
| Skin and Soft Tissue Infection |
0 |
0.12 |
| Cancer |
0 |
0.11 |
| Pregnancy |
0 |
0.11 |
| Vaginitis |
0 |
0.1 |
| Squamous Cell Carcinoma |
0 |
0.09 |
| Steroids |
0 |
0.09 |
| Cancer Risk |
0 |
0.08 |
| Cancer Survivor |
0 |
0.08 |
| Cosmetics |
0 |
0.07 |
| Health Care Reform |
0 |
0.07 |
| Dyspareunia |
0 |
0.06 |
| Revenue and Practice Management |
0 |
0.06 |
| Breast |
0 |
0.05 |
| Burnout |
0 |
0.05 |
| Corticosteroids |
0 |
0.05 |
| Incontinence |
0 |
0.05 |
| Overactive Bladder |
0 |
0.05 |
| Pain |
0 |
0.05 |
| Sexual Health |
0 |
0.05 |
| Clinical Research |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Refractory |
0 |
0.04 |
| Stress Incontinence |
0 |
0.04 |
| Tissue |
0 |
0.04 |
| Topical Corticosteroid |
0 |
0.04 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.03 |
| Biopsy |
0 |
0.03 |
| Brachial |
0 |
0.03 |
| Cardiovascular Imaging |
0 |
0.03 |
| Complementary and Alternative Medicine |
0 |
0.03 |
| Exercise |
0 |
0.03 |
| HIV Infection |
0 |
0.03 |
| Scar |
0 |
0.03 |
| Social Determinants of Health |
0 |
0.03 |
| Surgery |
0 |
0.03 |
| Topical Therapy |
0 |
0.03 |
| Urinary Tract Infection |
0 |
0.03 |
| Washington |
0 |
0.03 |
| Washington DC |
0 |
0.03 |
| Aromatase Inhibitors |
0 |
0.02 |
| Abscess |
0 |
0.01 |
| Adherence |
0 |
0.01 |
| Adjuvant Therapy |
0 |
0.01 |
| Bladder |
0 |
0.01 |
| Board Certification |
0 |
0.01 |
| Chronic Disease |
0 |
0.01 |
| Cytology |
0 |
0.01 |
| Dorsum |
0 |
0.01 |
| Echocardiography |
0 |
0.01 |
| Epithelium |
0 |
0.01 |
| Gynecological Examination |
0 |
0.01 |
| Hand |
0 |
0.01 |
| Health Care Quality, Access, and Evaluation |
0 |
0.01 |
| Histology |
0 |
0.01 |
| Hormonal Therapy |
0 |
0.01 |
| Hospital |
0 |
0.01 |
| Insurance |
0 |
0.01 |
| Mesh |
0 |
0.01 |
| Muscle |
0 |
0.01 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.01 |
| Outpatient Clinic |
0 |
0.01 |
| Physical Therapy |
0 |
0.01 |
| Postpartum |
0 |
0.01 |
| Pruritus |
0 |
0.01 |
| Radiofrequency (RF) Energy |
0 |
0.01 |
| Receptors |
0 |
0.01 |
| Stenosis |
0 |
0.01 |
| Stress |
0 |
0.01 |